# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-23-020926
Filing Date
2023-04-27
Accepted
2023-04-27 16:08:50
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM DEFA14A | ny20007748x2_defa14a.htm | DEFA14A | 17007
2 |  | ny20007748x2_nc1.jpg | GRAPHIC | 363084
3 |  | ny20007748x2_nc2.jpg | GRAPHIC | 402367
| Complete submission text file | 0001140361-23-020926.txt |  | 1072219

Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40502 | Film No.: 23856875
SIC: 2834 Pharmaceutical Preparations